Laser & Skin Surgery Center of Inidana
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hanke, C William
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Active, not recruiting
3
187
US
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Biofrontera Bioscience GmbH
Superficial Basal Cell Carcinoma
03/24
02/29
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Active, not recruiting
3
172
US
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratoses
08/25
05/26
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Completed
1
112
US
BF-200 ALA and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratosis, Keratosis, Actinic, Keratosis
04/23
04/23
MOSAIC, NCT06600152: Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients with Clean Surgical Wounds.

Recruiting
N/A
50
US
MAP Wound Matrix, DuoDerm
Tempo Therapeutics
Wound Heal
05/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hanke, C William
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Active, not recruiting
3
187
US
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Biofrontera Bioscience GmbH
Superficial Basal Cell Carcinoma
03/24
02/29
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Active, not recruiting
3
172
US
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratoses
08/25
05/26
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Completed
1
112
US
BF-200 ALA and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratosis, Keratosis, Actinic, Keratosis
04/23
04/23
MOSAIC, NCT06600152: Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients with Clean Surgical Wounds.

Recruiting
N/A
50
US
MAP Wound Matrix, DuoDerm
Tempo Therapeutics
Wound Heal
05/25
06/25

Download Options